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Introduction: Perioperative blood transfusion is associated with reduced prognosis in a number of solid
malignancies. We investigate its role in a head & neck squamous cell cancer (HNSCC) cell lines. Growth of these cell
lines was analogous to endothelial growth. Direct exposure to transfusion products exaggerated this effect. It was
logical therefore to assess the effects of anti-endothelial antibodies on this interaction.
Materials and methods: Control (HUVEC) and tumour cell lines were exposed to transfusion products. The
pre-incubation of the transfusion product with anti-endothelial growth factors was assessed by a growth assay.
Where appropriate cells were pre-incubated for 1 hour with 10 μl of a mixture of 100 μl of each and anti-ligand
antibodies, the corresponding blood product supplement was incubated with 10 μl of a mixture of 100 μl each of
anti-ligand antibodies 1 hour before supplementation to the appropriate cell line. All results are representative of at
least two independent experiments carried out in triplicate.
Results: The antibody did not directly reduce growth in the tumour cell line, however there was a significant
reduction (p< 0.001) in tumour cell line vascular mimicry caused by transfusion products pre-incubation with
anti-endothelial growth factor antibody. This was found in several other tumours.
Conclusion: Perioperative blood transfusion is associated with reduced prognosis in a number of solid
malignancies including HNSCC. However this phenomenon is abrogated by the use of anti-endothelial growth
factor antibodies. This suggests that the original effect was mediated by the endothelial growth factor family.Introduction
The perception of blood transfusion in the perioperative
setting has moved from a benign intervention, occasion-
ally life saving, to an outcome to be avoided. The recog-
nition in the mid 1980’s that blood transfusion carried
the risk of HIV infection forced a re-evaluation of the
indications for transfusing a surgical patient [1]. Peri-
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reproduction in any medium, provided the orassociated with reduced prognosis in a number of solid
malignancies [2].
Transfusion is in essence a transplant of allogenic cells
and its risks are not negligible. Allogeneic blood transfu-
sion is the most frequent allo-transplantation procedure
performed on a routine basis with no prior HLA-typing.
50% of the recipients of unprocessed red cells and
platelets become allo-immunised [3]. The potential for
transmission of unidentified viruses is unknown. The
deleterious consequences of blood transfusion arise from
many sources. Transfusion is also known to be immuno-
suppressive, and is an independent risk factor for noso-
comial infection and the recurrence of malignancy [4].
Blood is also an increasingly scarce resource.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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worsened cancer prognosis was first proposed by Francis
in the Lancet [5]. Since then it has been established in
colorectal, cervical, breast and prostate cancer.
The tumour effects that worsen prognosis are tumour
growth and cancer spread. These are now thought to be
facilitated in some way by transfusion, causing the over-
all prognosis to decline [1–5].
Such facilitation may be active (i.e. a direct effect) or
passive (i.e. an indirect immuno-depressive effect). Lit-
erature and previous research has focused upon the later
passive effect, regarding a blood transfusion as simply a
means of delivering oxygen carrying capacity and vol-
ume expansion with little regard either to the other cells
and components also transfused within the packed red
blood cells or even the non-haemoglobin contents of the
red cells themselves [3–8].
Determining the adverse effects of perioperative
transfusion is difficult in head and neck cancer patients
because of several confounding factors. Often the mu-
cosal disease process causes cachexia (not only through
dysphagia) with its effect on local tropic mucosal and
systemic immunity allowing tumour progression. Some
preliminary studies have occurred in the head and
neck but the results from these were conflicting due
mainly to the lack of consideration to confounding
factors [6–8]:
A) The patients are severely compromised anyway, and
that the group is self selected because only the more
prognostically challenged patients are likely to require a
transfusion [6–8].
This is supported from studies upon cancer of the colon,
rectum, cervix and prostate, Blumberg concluded that
transfusion of whole blood may represent a surrogate
marker for advanced or more aggressive clinical disease
[6–8].
B) The Transfusion has an immune modulating effect
(similar to a graft versus host effect) allowing the
tumour to escape host immuno-surveillance [6–8].
It was found that allogeneic transfusions were asso-
ciated with increase in cancer recurrence rates (80% in
colorectal cancer) and postoperative bacterial infections
(200% to 1000%). A possible mechanism was suggested
to be anergy due to presence of large amounts of anti-
gens. This immune dys-regulation caused by transfusion
augmented by the effects of haemorrhage, anaesthesia,
and surgical stress combine to create an adverse overall
effect [9].
Previous efforts to explain the possible effects of
blood transfusion on the recurrence of colorectal cancer
have been based entirely on the immunosuppressive
effects of blood transfusion. However the relationship
between solid tumour development and the immune
system is inconclusive. Investigators did not take intoaccount that transfusion may have a direct effect on
tumours [10].
The common and erroneous assumptions about blood
transfusions include the ideas that a unit of red blood
cells contain only red cells, that red cells only carry oxy-
gen and carbon dioxide, and that platelets provide only
clotting factors. In fact, pure blood products are rarely
clinically achievable and most transfusions, even leuco-
depleted packed red cells, contain a mixture of compo-
nents. These include a significant number of white blood
cells (monocytes and neutrophils) and platelets, some of
which contain high concentrations of physiologically
biologically active substances [11]. The different blood
product components contain these substances to differ-
ent degrees [12–16].
The ‘red cell lesion’ of ATP depletion and cell mem-
brane dysfunction with age-related fragility has been
known for some time [17], as well as the fact that par-
ticularly platelets contain many biologically active sub-
stances. It is believed that as result of normal
physiological aging and metabolic processes with deple-
tion of ATP and reduction of active membrane pro-
cesses, there is leaching of biologically active substances
from the cells into stored blood [18]. These leached
bioactive substances which include epidermal growth
factor (EGF), fibroblast growth factor (FGF) and vascu-
lar endothelial growth factor (VEGF) have immuno-
modulatory effects, which may in part explain the
increased likelihood of postoperative sepsis [19–25] and
adult respiratory distress syndrome in transfusion reci-
pients [20,22]. They also promote cell growth and
angiogenesis, and may therefore have a direct effect on
tumour growth [2].
Given the above, it is proposed that the extra-cellular
accumulation of bioactive factors in blood transfusion
products can directly [2] and indirectly cause tumour
growth and hence a worsening of prognosis.
Cancer Data from patients with colon, rectum, cervix
and prostate cancer showed an association between
transfusion, of any amount of whole blood, or larger
amounts of packed red blood cells, and later recurrence
of cancer. Recipients of any amounts of whole blood had
similar recurrence rates (38-52%). Proportional hazard
risk analysis showed that transfusion of any whole blood
or more than three units of red blood cells was signifi-
cantly associated with earlier recurrence and death due
to cancer [26].
We investigate the role of blood product transfusion
in a head & neck squamous cell cancer (HNSCC) cell
line. Growth of these cell lines was analogous to endo-
thelial cell line growth. Direct exposure to transfusion
products exaggerated this effect. It was logical therefore
to assess the effects of anti-endothelial antibodies on this
interaction.
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Control (HUVEC) and tumour cell lines were exposed
to transfusion products. The pre-incubation of the trans-
fusion product with anti-endothelial growth factors was
assessed by a growth assay [2].
The cell lines used were HUVEC, HN5a, 5b, 11a, 11b,
HCT116, DU145. Cells were grown in culture in culture
flasks (Costar 75 cm2 Vent Cap) in their appropriate
growth media (DMEM with 10% Fetal Calf Serum, 5%
CO2). Cells were grown to 75% confluence and serum
starved for 24 to 48 hours before use. Experiments were
carried out using the appropriate serum free medium for
each cell line. Mycoplasma assays were carried out to ex-
clude infection [27,28].
Pilot experiments were undertaken to assess growth of
a bank of tumour cell lines on (growth factor reduced)
matrigel (Sigma) with standard media (DMEM with 10%
Fetal Calf Serum).
The cells were incubated at 37°C with 5% CO2. Phase
contrast photomicrographs (Olympus systems) were
taken at 4 hours and 24 hours. Image analysis was per-
formed by using Image Pro Plus 4.0 computer image
analysis software, particular features of interest were two
dimensional area (surrogate of growth and migration),
branch points and end point measurements (surrogate
of intercellular complexity).
A modified growth assay was undertaken cells
whereby cells were grown to 75% confluence and plated
directly upon a 96 well plate at a seeding density of
2*103 cells per well, and serum starved for 24 hours.
The cells were then grown in serial dilutions of either
pure antibody mixture or blood product or a combin-
ation for a further 48 hours. 100 μl of alkaline phos-
phates substrate (3 mg/ml) was then added to each well,Figure 1 Graph showing area increase (mm2) of an endothelial cell lin
stored blood transfusion packed red cell products (pre-incubated wit
difference between growth of control samples and cell lines supplemented
as a significant difference between the effect of pre-incubation of supernat
(p< 0.001) with control and pure supernatant samples.incubated for 2 hours after which 50 μl of 1 M NaOH
was added and the plate placed in a microplate reader
and read at 405 nm wavelength.
Where appropriate cells were pre-incubated for 1 hour
with 10 μl of a mixture of 100 μl of each and anti-ligand
antibodies, the corresponding blood product supplement
was incubated with 10 μl of a mixture of 100 μl each of
anti-ligand antibodies 1 hour before supplementation to
the appropriate cell line. All results are representative of
at least two independent experiments carried out in
triplicate.
Results
The supernatant of stored blood transfusion products
causes increased growth in the cell lines investigated,
both control vascular and tumour cell line (ﻼ1, p<
0.001). The antibody did not directly reduce growth in
the cell line, however there was a significant reduction
(ﻼ2, p< 0.001) in cell line growth caused by transfusion
products pre-incubation with anti-endothelial growth
factor antibody. This was also found in the other tumour
cell lines investigated, (Figures 1 and 2). This suggests
that there is a direct “growth and vascular mimicry pro-
motion” effect of supplementation with blood product
supernatant which is abrogated by the use of anti-endo-
thelial growth factor antibody but no cytotoxic effect of
the antibody per-se on the cell lines. This was confirmed
by separate growth assay.
Discussion
Our results, suggest a novel hypothesis, that there is a
direct “growth and vascular mimicry promotion” effect
of the supplementation of HNSCC cell lines with blood
product supernatant (Figure 3). This is specificallye (growth by vascular mimicry) after supplementation with
h anti-endothelial growth factor antibodies). There was a significant
with supernatant from blood transfusion products (p< 0.001) as well
ant with anti-endothelial growth factor antibodies on cell line growth
Figure 2 Showing the effect of the addition of blood product supernatant upon the growth of an endothelial cell line (HUVEC). A (top
left) represents a control group; B (top right) represents the control group with the addition of anti-endothelial growth factor antibody; C
(bottom left) represents the effect of incubation with blood product supernatant; D (bottom left) represents the effect on HUVEC growth in
media supplemented with blood product supernatant pre-incubated with anti endothelial growth factor. This is representative of the direct
effects of blood product supernatant upon the cell lines studied. The effect of anti-endothelial growth factor antibodies is similar, i.e. in reducing
vascular channel formation. There was a significant statistical difference between groups represented by ‘A, C and D’, but not between groups ‘A
and B’ suggesting there is a direct effect of supplementation with blood product supernatant which is abrogated by the use of anti-endothelial
growth factor antibody but no cytotoxic effect of the antibody per-se on the cell lines.
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Furthermore since HNSCC is known to secrete endo-
thelial growth factors (both in the serum and saliva)
which may act in an autocrine manner of residual
tumour cells [27,28], it seems a logical extension to
hypothesize that there is a direct growth effect caused by
exposure to similar growth factors leached from theFigure 3 Showing a diagrammatic representation of the direct effect
promote growth, vasculogenesis and angiogenesis.anucleate red cells, contaminating white cells and plate-
lets which are all found in a “unit” of “leukocyte”
depleted packed red cells.
We have shown some of the prognostically deleterious
effects of perioperative transfusion in head & neck cancer
patients are caused by the transfusion product’s release of
endothelial growth factors. This was also found to be
the case in several of the tumour groups (colonic andof growth factors in the supernatant of blood products, which
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reported. It can now be hypothesized that this is due to
the specific expression of receptors to these growth factors
in these tumour types which are not universally found.
This would explain why this phenomenon does not occur
for all tumour types.
Conclusion
We wound tentatively suggest the following clinical
implications and adjustments to practice. If possible we
would avoid transfusions by meticulous technique and
haemostasis, plasma expansion and oxygenation. Alter-
natives to the antiquitidated "10/30" transfusion trigger
(i.e. haemoglobin less than 10 g/dL or haematocrit less
than 30) should be sought including the use of synthetic
blood analogues and recombinant erythropoietin. If
transfusion is inevitable then the minimal necessary
amount, to alleviate symptoms with due consideration
to the patients pre-morbid cardio-respiratory status,
should be given. The use of specific anti-endothelial
growth factor antibody filters before transfusion may be
mooted although simple red cell washing before transfu-
sion may be simpler and more cost effective.
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